In This Article
Ask most men to name ED medications and they'll say Viagra and Cialis. Maybe Stendra if they've been researching. Almost nobody mentions Levitra (vardenafil) — which is strange, because it's been FDA-approved since 2003 and works just as well as either of them.
Vardenafil didn't lose the ED medication race because it failed clinically. It lost because Pfizer and Eli Lilly outspent its manufacturer in advertising. Viagra became synonymous with ED treatment. Cialis carved out the "weekend pill" positioning. Levitra got squeezed out of public awareness despite being a perfectly effective, well-tolerated medication.
Here's why it deserves a second look — and when it might actually be the best option for you.
What Happened to Levitra?
Levitra launched in 2003, five years after Viagra and the same year as Cialis. The ED treatment market was exploding, but the advertising war favored deep pockets. Pfizer was spending hundreds of millions annually on Viagra marketing. Lilly invested heavily in Cialis's "36-hour window" positioning. Bayer/GSK, Levitra's manufacturers, couldn't match that spend.
The result: by the time all three went generic (sildenafil in 2017, tadalafil and vardenafil in 2018), Viagra and Cialis had decades of brand recognition. Telehealth platforms primarily stocked sildenafil and tadalafil because that's what men asked for. Vardenafil became the forgotten middle child.
But pharmacologically, there was never a good reason to ignore it. Vardenafil is approximately equipotent to sildenafil, has a comparable duration, and has some genuine clinical advantages in its side-effect profile.
How Vardenafil Compares Pharmacologically
Vardenafil is a PDE5 inhibitor — same mechanism as sildenafil and tadalafil. It blocks the enzyme that degrades cGMP, allowing greater blood flow during arousal. The key pharmacological differences:
| Factor | Vardenafil | Sildenafil | Tadalafil |
|---|---|---|---|
| Onset | 25–60 min | 30–60 min | 30–45 min |
| Duration | 4–6 hours | 4–6 hours | Up to 36 hours |
| Half-life | 4–5 hours | 3–5 hours | 17.5 hours |
| PDE5 selectivity | High | Moderate | Moderate |
| PDE6 cross-reactivity (vision) | Lower | Higher | Low |
| Food interaction | Moderate (high-fat delays) | Significant | Minimal |
| Daily use option | No | No | Yes |
| Standard doses | 5mg, 10mg, 20mg | 25mg, 50mg, 100mg | 2.5mg, 5mg, 10mg, 20mg |
| Generic price | $5–$15/pill | $2–$8/pill | $1–$10/pill |
The takeaway: vardenafil sits between sildenafil and tadalafil in most respects. Similar to sildenafil in duration and onset, but with a slightly cleaner PDE6 profile (fewer visual side effects). Not as long-lasting as tadalafil, but without tadalafil's tendency toward back pain and myalgia (PDE11 effects).
Staxyn: The Unique ODT Formulation
Vardenafil has one formulation that no other PDE5 inhibitor offers: Staxyn, an orally disintegrating tablet (ODT) that dissolves on the tongue without water.
Staxyn isn't just regular vardenafil in a dissolvable form. It uses a different delivery system (OraVescent technology) that changes the absorption pathway — part of the drug enters through the oral mucosa rather than entirely through the GI tract. Because of this difference:
- Staxyn comes only in a 10mg dose (not interchangeable with 10mg standard vardenafil)
- It should not be swallowed whole — it must dissolve on the tongue
- It should not be taken with liquid, which can wash the drug into the stomach before buccal absorption occurs
- Onset may be slightly faster than standard vardenafil in some men
The practical advantage is discretion and convenience. No water needed, no swallowing a tablet, nothing to carry beyond the blister pack. For men who want maximum discretion — say, in a dating context — this matters.
Staxyn (vardenafil ODT) is NOT interchangeable with standard vardenafil tablets. Different dose, different absorption pathway. Your pharmacist cannot substitute one for the other.
Side Effect Profile: Where Vardenafil Wins
Vardenafil's side effects are generally comparable to sildenafil's, with one notable improvement: fewer visual disturbances. Sildenafil's cross-reactivity with PDE6 (the phosphodiesterase isoenzyme in the retina) causes blue-tinged vision, increased brightness sensitivity, or blurred vision in approximately 3% of users. Vardenafil has lower PDE6 affinity, making these visual effects less common.
Common vardenafil side effects include:
- Headache (~15%) — comparable to sildenafil
- Flushing (~11%) — slightly higher than sildenafil
- Nasal congestion (~9%)
- Dyspepsia (~4%)
- Dizziness (~2%)
Notably, vardenafil does not cause the back pain and myalgia associated with tadalafil's PDE11 cross-reactivity. So if you've tried tadalafil and couldn't handle the back pain, and you've tried sildenafil and got the blue vision, vardenafil occupies a useful middle ground.
One specific caution: vardenafil carries a slightly higher risk of QT interval prolongation than other PDE5 inhibitors. Men with known QT prolongation, those taking Class IA or III antiarrhythmic medications, and those with congenital long QT syndrome should discuss this with their prescriber.
When Vardenafil Is the Right Choice
Consider Vardenafil If:
- You've tried sildenafil and experienced visual disturbances (blue vision, light sensitivity)
- You've tried tadalafil and couldn't tolerate the back pain or myalgia
- You want a short-acting medication (4–6 hours) without sildenafil's visual side-effect risk
- You'd value the Staxyn ODT formulation for discretion (no water, dissolves on tongue)
- You prefer the middle ground between sildenafil's side effects and tadalafil's long duration
Vardenafil Probably Isn't the Best Fit If:
- You want continuous readiness — daily tadalafil is the only option for that
- You want the cheapest possible option — generic sildenafil ($2–$8) beats vardenafil ($5–$15)
- You've never tried any ED medication — start with sildenafil or tadalafil (better studied, cheaper, more widely available)
- You have a known QT prolongation or take antiarrhythmic medications
Generic Vardenafil Pricing in 2026
Generic vardenafil has been available since 2018, but it remains slightly more expensive than generic sildenafil or tadalafil — typically $5–$15 per pill through telehealth platforms. This isn't because the drug is inherently more expensive to manufacture; it's because lower demand means less competitive pressure.
Staxyn (the ODT version) remains significantly more expensive, often $25+ per dose, with limited generic availability. If cost is a priority, standard vardenafil tablets offer the same active ingredient at a fraction of the Staxyn price.
Where to Get Vardenafil Online
Not every telehealth platform stocks vardenafil (most focus on the higher-demand sildenafil and tadalafil), but several do offer it:
| Provider | Medications | Highlights | |
|---|---|---|---|
| BraveRX | Multiple ED options including compounds | Compound formulas, 24/7 support, daily dosing | Visit Site → |
| MyDrHank | Sildenafil, tadalafil, vardenafil | Pharmacy-owned, transparent pricing from ~$1.67/pill | Visit Site → |
Find the Right ED Medication for You
Whether vardenafil, sildenafil, or tadalafil is the best fit depends on your specific situation. A telehealth consultation can help you decide.
Compare Providers → Sildenafil vs. TadalafilFrequently Asked Questions
No. They're different molecules, both PDE5 inhibitors. They have similar efficacy and duration (4–6 hours), but vardenafil has slightly lower incidence of visual side effects and a slightly different food interaction profile.
Staxyn is an orally disintegrating tablet (ODT) form of vardenafil that dissolves on the tongue. It uses a different dose (10mg) and is not interchangeable with standard vardenafil tablets because the absorption pathway differs.
Marketing, not efficacy. Pfizer's Viagra and Lilly's Cialis dominated ED advertising spending. By the time generics arrived, sildenafil and tadalafil had massive brand recognition. Vardenafil is equally effective but lost the awareness battle.
Related reading: Sildenafil vs. Tadalafil Comparison · Stendra (Avanafil) Review · ED Medication Costs in 2026